| Symbol | ARVN |
|---|---|
| Name | ARVINAS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 395 WINCHESTER AVENUE,5 SCIENCE PARK, NEW HAVEN, Connecticut, 06511, United States |
| Telephone | +1 203 535-1456 |
| Fax | — |
| — | |
| Website | https://www.arvinas.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The companys proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cells own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases. The groups product candidates are bavdegalutamide, ARV-471 and ARV-766. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - ARVINAS, INC. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-000640 <b>Size:</b> 7 KB
Read moreBerkowitz Noah 🔴 sold 6.4K shares of ARVINAS, INC. (ARVN) at $11.10 Transaction Date: Mar 18, 2026 | Filing ID: 019950
Read more(90% Positive) ARVINAS, INC. (ARVN) Announces Clinical Development Update
Read moreArvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days
Read moreNew Form 4/A - ARVINAS, INC. <b>Filed:</b> 2026-03-12 <b>AccNo:</b> 0001628280-26-017385 <b>Size:</b> 5 KB
Read moreArvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
Read moreDirector Morrison Briggs 🟢 acquired 20.0K shares of ARVINAS, INC. (ARVN) at $13.40 Transaction Date: Mar 06, 2026 | Filing ID: 016003
Read moreLoomis David K 🟢 acquired 30.9K shares (1 derivative) of ARVINAS, INC. (ARVN) at $13.38 Transaction Date: Feb 26, 2026 | Filing ID: 013537
Read moreCacace Angela M 🟢 acquired 112.0K shares (1 derivative) of ARVINAS, INC. (ARVN) at $13.38 Transaction Date: Feb 26, 2026 | Filing ID: 013535
Read moreBerkowitz Noah 🟢 acquired 112.0K shares (1 derivative) of ARVINAS, INC. (ARVN) at $13.38 Transaction Date: Feb 26, 2026 | Filing ID: 013533
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07023731 | A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G1… | Phase1 | KRAS G12D Mutation | Recruiting | 2025-05-29 | 2029-04-02 | ClinicalTrials.gov |
| NCT06393738 | A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. | Phase1 | Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) | Recruiting | 2024-09-05 | 2028-03-01 | ClinicalTrials.gov |
| NCT06347861 | A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Ta… | Phase1 | Healthy | Completed | 2024-04-02 | 2024-08-08 | ClinicalTrials.gov |
| NCT05548127 | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given… | Phase1 | Breast Cancer | Active_Not_Recruiting | 2023-02-23 | 2026-09-01 | ClinicalTrials.gov |
| NCT05549505 | A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cance… | Phase2 | Breast Cancer | Completed | 2023-02-15 | 2024-07-25 | ClinicalTrials.gov |
| NCT05501769 | ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metasta… | Phase1 | Breast Cancer | Completed | 2022-09-08 | 2025-08-25 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Dabigatran etexilate | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05673889 |
| ARV-471 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05673889 |
| Fulvestrant | DRUG | Phase PHASE3 | Advanced Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05654623 |
| ARV-471 | DRUG | Phase PHASE3 | Advanced Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05654623 |
| [oxoisoindolin-14C]ARV-471 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05930925 |
| [phenyl-14C]ARV-471 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05930925 |
| Carbamazepine | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06005688 |
| esomeprazole | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT06275841 |
| Rosuvastatin | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05652660 |
| Itraconazole | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05538312 |
| single dose of vepdegestrant as tablet formulation (Treatment C) | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT06347861 |
| Vepdegestrant | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06005688 |
| Midazolam | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06256510 |
| single dose of vepdegestrant as tablet formulation (Treatment B) | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT06347861 |
| single dose of vepdegestrant as tablet formulation (Treatment A) | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT06347861 |
| Vepdegestrant (Test) | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06911788 |
| Vepdegestrant (Reference) | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06911788 |
| ARV-110 in Combination with Abiraterone | DRUG | Phase PHASE1 | Prostate Cancer Metastatic | COMPLETED | NCT05177042 |
| ARV-471 in combination with Everolimus | DRUG | Phase PHASE1 | Breast Cancer | COMPLETED | NCT05501769 |
| Samuraciclib | DRUG | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06125522 |
| Letrozole | DRUG | Phase PHASE3 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05909397 |
| Vepdegestrant (ARV-471/PF-07850327) | DRUG | Phase PHASE3 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05909397 |
| Abemaciclib | DRUG | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05548127 |
| ARV-471 in combination with palbociclib (IBRANCE®) | DRUG | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04072952 |
| PF-07220060 | DRUG | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06206837 |
| Ribociclib | DRUG | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05573555 |
| vepdegestrant | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT06275841 |
| ARV-806 | DRUG | Phase PHASE1 | KRAS G12D Mutation | RECRUITING | NCT07023731 |
| Glofitamab | DRUG | Phase PHASE1 | Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) | RECRUITING | NCT06393738 |
| ARV-393 | DRUG | Phase PHASE1 | Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) | RECRUITING | NCT06393738 |
| Surgical resection of breast tumor | PROCEDURE | Phase PHASE2 | Breast Cancer | COMPLETED | NCT05549505 |
| Anastrozole | DRUG | Phase PHASE2 | Breast Cancer | COMPLETED | NCT05549505 |
| ARV-471 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05652660 |
| ARV-110 | DRUG | Phase PHASE1 | Prostate Cancer Metastatic | COMPLETED | NCT03888612 |